5 Dumbest Things on...
Health Care: Drugs
Nektar Therapeutics Inc. (NKTR: NASDAQ)
$9.27 -0.04 | -0.38%
05/24/13 - 04:00 PM ET
Company Cash Flow
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Cash Flow From Operating Activities | ||||
|---|---|---|---|---|
| Net Income (Loss) | -171.86M | -133.98M | -37.94M | -102.52M |
| Operating Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Extraordinary Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Receivables | -867.00K | 20.16M | -20.30M | 6.03M |
| (Increase) Decrease in Inventories | -5.61M | -5.39M | -795.00K | 2.85M |
| (Increase) Decrease In Other Current Assets | 0.00 | 0.00 | 0.00 | -200.00K |
| (Decrease) Increase In Payables | -122.00K | -3.38M | 4.27M | -8.05M |
| (Decrease) Increase In Other Current Liabilities | 8.29M | 4.38M | -1.14M | -9.16M |
| (Increase) Decrease In Other Working Capital | -78.00K | -30.73M | -46.70M | 126.24M |
| Other Non-Cash Items | 7.93M | 20.24M | 30.17M | 9.67M |
| Net Cash From Continuing Operations | -129.76M | -113.74M | -55.87M | 39.74M |
| Net Cash From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | -129.76M | -113.74M | -55.87M | 39.74M |
| Sale of Property, Plant & Equipment | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Used for Investing Activities | ||||
| Sale of Short-Term Investments | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchases of Property, Plant & Equipment | -10.58M | -9.72M | -31.46M | -20.70M |
| Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchases of Short-Term Investments | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Cash from Investing Activities | -19.62M | 210.09M | 0.00 | -4.44M |
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | 113.02M | -111.95M | 16.71M | -149.04M |
| Issuance of Debt | 77.94M | 0.00 | 0.00 | 0.00 |
| Cash Used for Financing Activities | ||||
| Issuance of Capital Stock | 4.12M | 224.31M | 8.89M | 4.82M |
| Repayment of Long-Term Debt | -174.84M | -1.98M | -1.36M | -1.28M |
| Repurchase of Capital Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Payment of Cash Dividends | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Charges, Net | 119.59M | 0.00 | 0.00 | 0.00 |
| Net Cash From Financing Activities | 26.80M | 222.34M | 7.54M | 3.54M |
| Effect of Exchange Rate Changes | 60.00K | 916.00K | -219.00K | -226.00K |
| Net Change in Cash & Cash Equivalents | 10.12M | -2.44M | -31.84M | -105.99M |
Portfolios with NKTR
- Portfolio NameUser Type
- ContributorStocks Under-$10 Moving Hig...
- ContributorBreakout Stocks Of The Week...
- ContributorBreakout Stocks Of The Week...
- Contributor22 Biopharma Stocks With Br...
- Contributor10 Health Care Stocks With ...
- Contributor10 Mid-Caps With Upside
- Contributor10 Pharma Stocks With Upside
- ProDriehaus Capital
- UserSUPRATRADE 7 Top Stocks for...
- UserSUPRATRADE 10 Stock Picks F...
Latest NKTR Headlines from TheStreet
- 4 Stocks Under $10 Spiking Higher 02.22.13 | 03:02 pm
- 5 Stocks Poised for Breakouts 02.01.13 | 01:02 pm
- J.P. Morgan Healthcare Confab Live Blog Day Three 01.09.13 | 10:01 am
- Biotech 2013 Kickoff Party: J.P. Morgan Investor Confab 01.04.13 | 08:01 am
- A Buysider's Preview of Biotech's Biggest Conference 01.02.13 | 07:01 am
- AstraZeneca, Nektar Opioid Constipation Drug May Have Failed Phase III Study 11.13.12 | 10:11 am
- FDA Places New Heart-Safety Hurdle in Path of Opioid Constipation Drugs 11.12.12 | 10:11 am
- 21 Most Volatile Biopharma Stocks Closing Out 2012 11.05.12 | 06:11 am
- 5 Stocks Poised for Breakouts 09.28.12 | 01:09 pm
- Nektar Therapeutics Is a Short 09.12.12 | 07:09 am
Press Releases for NKTR
- Nektar Therapeutics' President And CEO, Howard W. Robin, To Present At The 2013 UBS Global Healthcare Conference In New York City - PR Newswire 05.16.13 | 06:05 pm
- Bayer Initiates Phase III Trial Of Investigational Inhaled Amikacin Solution (BAY41-6551T) In Mechanically Ventilated Patients With Gram-negative Pneumonia - PR Newswire 04.16.13 | 05:04 am
- Nektar Therapeutics To Present At The 33rd Annual Cowen And Company Healthcare Conference In Boston - PR Newswire 03.01.13 | 04:03 pm
- AstraZeneca Announces Results From Long-Term Safety Trial Of Naloxegol In Patients With Opioid-Induced Constipation - PR Newswire 02.26.13 | 06:02 am
- Nektar Therapeutics' President And CEO, Howard W. Robin, To Present At The 31st Annual J.P. Morgan Healthcare Conference In San Francisco, CA - PR Newswire 01.04.13 | 08:01 am
- Nektar To Announce Financial Results For The Third Quarter Of 2012 On Tuesday, November 13, 2012, After Close Of U.S.-Based Financial Markets - PR Newswire 11.06.12 | 05:11 pm
- Nektar Therapeutics' President And CEO, Howard W. Robin, To Present At The UBS 2012 Global Life Sciences Conference In New York City - PR Newswire 09.13.12 | 09:09 am
- Nektar To Announce Financial Results For The Second Quarter Of 2012 On Thursday, August 9, 2012, After Close Of U.S.-Based Financial Markets - PR Newswire 08.02.12 | 03:08 pm
- Nektar Therapeutics Announces Private Placement Of $125 Million Of Senior Secured Notes Due In 2017 - PR Newswire 07.10.12 | 08:07 am
- Nektar To Host Investor And Analyst R&D Day In New York City - PR Newswire 04.10.12 | 08:04 am
Partner Headlines for NKTR
- UPDATE: Bank of America Lowers Nektar Therapeutics PO, Maintains Underperform - Benzinga 11.13.12 | 09:11 am
- UPDATE: Jefferies & Company Downgrades Nektar Therapeutics to Hold, Lowers PT - Benzinga 11.12.12 | 09:11 am
- Nektar Therapeutics Says Got Positive Data from Phase 1a Study of NKTR-192 - Benzinga 09.18.12 | 09:09 am
- Long Undervalued, Is Alkermes Still A Bargain? - Seeking Alpha 03.30.12 | 09:03 am
- The Age Of Personalized Medicine Has Arrived - Seeking Alpha 03.08.12 | 09:03 am
- Company News for March 1, 2012 - Corporate Summary - Zacks 03.01.12 | 10:03 am
- What's It Going To Take To Get Salix Cheap? - Seeking Alpha 02.29.12 | 08:02 am
- Nektar Therapeutics Presents Positive Results from Phase 2 Clinical Study of NKTR-102 in Metastatic Breast Cancer - Benzinga 09.10.11 | 04:09 pm
- 10 Stocks With Bullish Momentum Backed By Strong Top Line Growth - Seeking Alpha 08.24.11 | 08:08 am
- 14 Oversold Stocks Trading Near Lows but Being Bought Up by the Smart Money - Seeking Alpha 07.12.11 | 09:07 am
